175 related articles for article (PubMed ID: 35086762)
1. Propensity-Weighted Survival Analysis of SBRT vs. Conventional Radiotherapy in Unfavorable Intermediate-Risk Prostate Cancer.
Andruska N; Fischer-Valuck BW; Agabalogun T; Carmona R; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Baumann BC
Clin Genitourin Cancer; 2022 Apr; 20(2):123-131. PubMed ID: 35086762
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer.
Patel SA; Switchenko JM; Fischer-Valuck B; Zhang C; Rose BS; Chen RC; Jani AB; Royce TJ
Radiat Oncol; 2020 Sep; 15(1):217. PubMed ID: 32933541
[TBL] [Abstract][Full Text] [Related]
3. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy.
Andruska N; Agabalogun T; Fischer-Valuck BW; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Carmona R; Baumann BC
Brachytherapy; 2022; 21(5):617-625. PubMed ID: 35641370
[TBL] [Abstract][Full Text] [Related]
4. Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer.
Andruska N; Michalski JM; Carmona R; Agabalogun T; Brenneman RJ; Gay HA; Fischer-Valuck BW; Baumann BC
Brachytherapy; 2022; 21(3):317-324. PubMed ID: 35123889
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Patients With Unfavorable Intermediate-Risk Prostate Cancer Treated With External-Beam Radiotherapy Versus Brachytherapy Alone.
Andruska N; Fischer-Valuck BW; Carmona R; Agabalogun T; Brenneman RJ; Gay HA; Michalski JM; Baumann BC
J Natl Compr Canc Netw; 2022 Feb; 20(4):343-350.e4. PubMed ID: 35193114
[TBL] [Abstract][Full Text] [Related]
6. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
[TBL] [Abstract][Full Text] [Related]
7. The Association of Radiation Dose With Overall Survival for Patients Treated With Prostate Stereotactic Body Radiation Therapy.
Waters MR; Andruska N; Fischer-Valuck BW; Agabalogun T; Brenneman RJ; Gay H; Michalski JM; Baumann B
Cureus; 2023 Jan; 15(1):e34351. PubMed ID: 36874706
[TBL] [Abstract][Full Text] [Related]
8. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis.
Tchelebi LT; Lehrer EJ; Trifiletti DM; Sharma NK; Gusani NJ; Crane CH; Zaorsky NG
Cancer; 2020 May; 126(10):2120-2131. PubMed ID: 32125712
[TBL] [Abstract][Full Text] [Related]
9.
Smile TD; Tom MC; Halima A; Ciezki JP; Reddy CA; Stephans KL; Mian OY; Zhang RX; Klein EA; Campbell S; Ulchaker J; Angermeier K K; Tendulkar RD
Brachytherapy; 2022; 21(1):85-93. PubMed ID: 34656435
[TBL] [Abstract][Full Text] [Related]
10. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
[TBL] [Abstract][Full Text] [Related]
11. Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized Prostate Cancer.
Poon DMC; Lam D; Wong KCW; Chu CM; Cheung M; Mo F; Suen J; Ng CF; Chan ATC
Curr Oncol; 2021 Dec; 29(1):27-37. PubMed ID: 35049677
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer.
Haque W; Verma V; Polamraju P; Farach A; Butler EB; Teh BS
Radiother Oncol; 2018 Nov; 129(2):264-269. PubMed ID: 30031630
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.
Amini A; Rusthoven CG; Jones BL; Armstrong H; Raben D; Kavanagh BD
Urol Oncol; 2016 Apr; 34(4):165.e1-9. PubMed ID: 26699831
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial.
Zhao X; Wang T; Ye Y; Li J; Gao X; Zhang H
BMJ Open; 2022 Sep; 12(9):e051371. PubMed ID: 36180115
[TBL] [Abstract][Full Text] [Related]
15. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
16. Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer.
Saeed NA; Jin L; Amini A; Verma V; Lester-Coll NH; Chen PH; Decker RH; Park HS
Am J Clin Oncol; 2023 Feb; 46(2):66-72. PubMed ID: 36662872
[TBL] [Abstract][Full Text] [Related]
17. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
[TBL] [Abstract][Full Text] [Related]
18. Whole Pelvic Radiotherapy With Stereotactic Body Radiotherapy Boost vs. Conventionally Fractionated Radiotherapy for Patients With High or Very High-Risk Prostate Cancer.
Wang SC; Ting WC; Chang YC; Yang CC; Lin LC; Ho HW; Chu SS; Lin YW
Front Oncol; 2020; 10():814. PubMed ID: 32547949
[No Abstract] [Full Text] [Related]
19. Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-Only versus Whole Pelvic Radiation Therapy.
Andruska N; Fischer-Valuck BW; Waters M; Juarez Diaz E; Agabalogun T; Kim EH; Smith ZL; Brenneman RJ; Gay HA; Andriole GL; Michalski JM; Baumann BC
J Urol; 2022 Jun; 207(6):1227-1235. PubMed ID: 35085038
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
